We'd appreciate your feedback. Send feedback Subscribe to our newsletters and alerts


Pharmaceutical Sciences and Drug Design

2025 Volume 5

Inhibition of Pre-B Cell Colony Enhancing Factor Protects Against Lung Injury Following Cardiopulmonary Bypass in Rats


,
  1. Department of Biotechnology, Faculty of Science, University of Bucharest, Bucharest, Romania.
Abstract

Pre-B cell colony enhancing factor (PBEF) is recognized as a proinflammatory cytokine involved in acute lung injury, but its contribution to lung damage following cardiopulmonary bypass (CPB) has not been clarified. This study explored how reducing PBEF expression affects lung injury and the regulation of sodium and water transport in a rat model of CPB. Lung morphology was examined using hematoxylin and eosin staining. Immunohistochemistry was applied to assess PBEF levels. Western blotting was used to measure proteins related to sodium–water balance and to analyze associated signaling pathways. Rats subjected to CPB displayed marked alveolar wall injury and increased free PBEF levels compared with controls. CPB also led to elevated expression of PBEF, surfactant protein D, aquaporin 1, aquaporin 5, and the epithelial sodium channel. Administering an adenovirus carrying sh-PBEF lowered the expression of these proteins in CPB-treated rats. In addition, phosphorylation of ERK1/2, AKT, and p38 MAPK was heightened after CPB but decreased following sh-PBEF treatment. Delivering sh-PBEF through an adenoviral vector may help lessen CPB-induced lung damage and improve sodium and water transport in the lungs, possibly by suppressing MAPK, ERK1/2, and AKT signaling pathways.


How to cite this article
Vancouver
Stanescu V, Matei A. Inhibition of Pre-B Cell Colony Enhancing Factor Protects Against Lung Injury Following Cardiopulmonary Bypass in Rats. Pharm Sci Drug Des. 2025;5:196-204. https://doi.org/10.51847/VPckINGQTt
APA
Stanescu, V., & Matei, A. (2025). Inhibition of Pre-B Cell Colony Enhancing Factor Protects Against Lung Injury Following Cardiopulmonary Bypass in Rats. Pharmaceutical Sciences and Drug Design, 5, 196-204. https://doi.org/10.51847/VPckINGQTt
Articles
Evaluating the Clinical Efficacy of Antiviral Treatments for SARS-CoV-2
Pharmaceutical Sciences and Drug Design
Vol 1 , 2021 | Angelique Welman

About GalaxyPub

Find out more

Our esteemed publisher is committed to advancing medical knowledge through rigorous research dissemination. We exclusively accept submissions related to the field of medicine.

Our journals provide a platform for clinicians, researchers, and scholars to share groundbreaking discoveries, clinical insights, and evidence-based practices. By maintaining this specialized focus, we ensure that their publications contribute significantly to the advancement of healthcare worldwide.